Tvardi Therapeutics, Inc. (TVRD) stock
TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.18+0.02 (+2.16%)
Close on Nov 13, 2026Market cap $15.74MP/E –Yield 0.00%
Tvardi Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Tvardi Therapeutics's profit margin for the twelve months ending Mar 31, 2025 was -459.3%. For fiscal 2024 it was -411.9%, against -565.2% the year before. The highest annual figure on record is 6.2% in fiscal 2020.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -411.9% | +153.3 |
| FY2023 | Dec 31, 2023 | -565.2% | −361.1 |
| FY2022 | Dec 31, 2022 | -204.2% | +179.9 |
| FY2021 | Dec 31, 2021 | -384.1% | −390.3 |
| FY2020 | Dec 31, 2020 | 6.2% | +541.1 |
| FY2019 | Dec 31, 2019 | -534.9% | +14.6 |
| FY2018 | Dec 31, 2018 | -549.5% | +5830.8 |
| FY2017 | Dec 31, 2017 | -6380.4% | +60224.3 |
| FY2016 | Dec 31, 2016 | -66604.7% | −65955.4 |
| FY2015 | Dec 31, 2015 | -649.2% | −90.7 |
| FY2014 | Dec 31, 2014 | -558.5% | −525.4 |
| FY2013 | Dec 31, 2013 | -33.1% | +493.9 |
| FY2012 | Dec 31, 2012 | -527.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | -372.9% | −176.1 |
| Q4 FY2024 | Dec 31, 2024 | -873.3% | +203.1 |
| Q3 FY2024 | Sep 30, 2024 | -215.7% | +360.4 |
| Q2 FY2024 | Jun 30, 2024 | -703.8% | −249.8 |
| Q1 FY2024 | Mar 31, 2024 | -196.8% | +235.7 |
| Q4 FY2023 | Dec 31, 2023 | -1076.5% | −146.1 |
| Q3 FY2023 | Sep 30, 2023 | -576.1% | −361.7 |
| Q2 FY2023 | Jun 30, 2023 | -454.0% | −435.8 |
| Q1 FY2023 | Mar 31, 2023 | -432.5% | +146.8 |
| Q4 FY2022 | Dec 31, 2022 | -930.4% | +3135.7 |
| Q3 FY2022 | Sep 30, 2022 | -214.4% | −209.4 |
| Q2 FY2022 | Jun 30, 2022 | -18.3% | +1185.9 |
| Q1 FY2022 | Mar 31, 2022 | -579.3% | −649.7 |
| Q4 FY2021 | Dec 31, 2021 | -4066.0% | −3887.8 |
| Q3 FY2021 | Sep 30, 2021 | -5.0% | +439.9 |
| Q1 FY2021 | Mar 31, 2021 | -1204.2% | −846.8 |
| Q4 FY2020 | Dec 31, 2020 | 70.4% | +704.6 |
| Q3 FY2020 | Sep 30, 2020 | -178.2% | +389.5 |
| Q2 FY2020 | Jun 30, 2020 | -444.9% | −4.1 |
| Q1 FY2020 | Mar 31, 2020 | -357.4% | +143.8 |
| Q4 FY2019 | Dec 31, 2019 | -634.2% | −261.0 |
| Q3 FY2019 | Sep 30, 2019 | -567.7% | −184.5 |
| Q2 FY2019 | Jun 30, 2019 | -440.9% | +157.4 |
| Q1 FY2019 | Mar 31, 2019 | -501.1% | +1936.2 |
| Q4 FY2018 | Dec 31, 2018 | -373.3% | – |
| Q3 FY2018 | Sep 30, 2018 | -383.2% | – |
| Q2 FY2018 | Jun 30, 2018 | -598.3% | – |
| Q1 FY2017 | Mar 31, 2017 | -2437.3% | – |
See a number that looks wrong?